Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab pegol plus methotrexate in DMARD-naive early active rheumatoid arthritis
NL-OMON37680Phase 3Active, not recruiting
- Sponsor
- UCB
- Start
- Aug 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of certolizumab pegol and methotrexate in rheumatoid arthritis (RA), sponsored by UCB. Primary endpoints: Sustained remission at Week 52 and Maintenance of low disease activity through Week 104. Started Aug 2012; status: active, not recruiting.
02
Drugs
certolizumab pegolmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON37680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37680.